The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback